{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-24-000153","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.392979+00:00","generated_at":"2026-05-31T01:12:33.723886+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"low","headline":"Pliant Therapeutics amends bylaws to align with Delaware law and revise stockholder proposal procedures","bullets":["Board approved Third Amended and Restated Bylaws effective September 24, 2024.","Amendments align bylaws with Delaware law developments and include severability provision.","Revised procedural and disclosure requirements for stockholder director nominations and other business proposals.","Changes are ministerial and conforming; no substantive operational or financial impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-24-000153","json":"https://secwatch.observer/filing/0001746473-24-000153.json","markdown":"https://secwatch.observer/filing/0001746473-24-000153.md","text":"https://secwatch.observer/filing/0001746473-24-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000153/0001746473-24-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000153/plrx-20240924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:12:33.723886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}